BCL2L1 and neoplasm: Next, we confirmed that DT2216 and AZD8055 led to a significant reduction in BCL-XL and MCL-1 levels, respectively, which was associated with significant inhibition of mTOR substrates (p-4EBP1 and p-S6) upon AZD8055 treatment in H1048 tumor lysates.